Hippokratia 2003, 7(4):182-185
M Lubomirova, E Andreev, R Krasteva, R Djerassi, B Kiperova
Abstract
We evaluate the effect of HMG-Co A reductase inhibitor fluvasatin on lipid disorders and proteinuria in patients with nephrotic syndrome (NS).Seven female (F) and 12 male (M) pts, average age 39 years, with glomerular filtration rate (GRF) over 90 ml/min and NS with proteinuria over 4.0g/24 h and severe hyperlipidemia were investigated. All pts were treated with corticosteroids alone or in combination with cytotoxic drugs, because of the illness activity. Fluvastatin was administered 40 mg/d for 3 months. Tchol, TG, LDL, HDL and 24 hours proteinuria were examined before the start of the study and after 3 months.Administration of fluvastatine led to a significant reduction of lipid fractions: Tchol mean value (MV) before the treatment 9.3±3.2mmol/l and after 5.9±1.32mmol/l (p<0.001). TG: MV before 5.9± 1.87mmol/l and after 2.74±1.04 mmol/l (p<0,01). LDL: MV before 6.35±1.34 mmol/l and after 3.57±0.81 mmol/l (p<0.001). HDL levels were normal in all pts. MV before 1.61± 0.53 mmol/l and after 1.04 ± 0.23mmol/l (p=0.01).The changes of 24 hour proteinuria were not significant: MV before 4.21± 2.4 g/24h and after-3.03±1.68 g/24h (p= 0.10).Significant reduction of hyperlipidemia was detected in pts. with NS receiving corticosteroid treatment regardless of the fact that the nephrotic proteinuria remains and is not affected by fluvasatin.